Indolent evolution of a distal pancreatic adenocarcinoma with central osseous metaplasia managed by multivisceral resection, excisional biopsy of liver metastasis and adjuvant chemotherapy

Pancreatology ◽  
2019 ◽  
Vol 19 ◽  
pp. S64
Author(s):  
Sorin T. Barbu ◽  
Tudor Cerciu ◽  
Iacob Domsa ◽  
Doru Munteanu ◽  
Anca Mihailov
2017 ◽  
Vol 6 (2) ◽  
pp. 1546
Author(s):  
Nabil Khzam ◽  
Reza Shah Mansouri ◽  
Alexander Poli ◽  
Mahmoud M. Bakr

Fibrous epulis or peripheral ossifying fibroma is a reactive non-neoplastic condition that affects the gingiva as a result of chronic irritation. A case of a 44 year old female is presented in this study with a gingival swelling related to the maxillary central incisors. The Patient reported a history of trauma ten years ago and a recent root canal treatment of tooth 21, followed by referral to a specialist with a misdiagnosis for a combined periodontic-endodontic lesion affecting the maxillary central incisors. Excisional biopsy of the lesion revealed a diagnosis of ulcerated fibrous epulis with osseous metaplasia also known as peripheral ossifying fibroma. Periodontal debridement was performed to eliminate supra and subgingival plaque and calculus as well as gingival inflammation that could have been the source of irritation. The clinical and histopathological pictures and the surgical procedures associated with management of the periodontal disease are described. The etiological factor behind the development of the gingival reactive lesion remains unknown and could be the history of trauma, the chronic irritation induced by the plaque and calculus associated with the periodontal disease or a combination of both. We endeavour to follow up the case in order to report any recurrence.


JAMA Oncology ◽  
2021 ◽  
Author(s):  
Winta T. Mehtsun ◽  
Nadine J. McCleary ◽  
Ugwuji N. Maduekwe ◽  
Brian M. Wolpin ◽  
Deborah Schrag ◽  
...  

2019 ◽  
Vol 2019 (3) ◽  
Author(s):  
Sudha Pandit ◽  
Hrishikesh Samant ◽  
Kapil Kohli ◽  
Hosein M Shokouh-Amiri ◽  
Gregory Wellman ◽  
...  

2012 ◽  
Vol 83 (2) ◽  
pp. 559-565 ◽  
Author(s):  
Kazuhiko Ogawa ◽  
Yoshinori Ito ◽  
Naoki Hirokawa ◽  
Keiko Shibuya ◽  
Masaki Kokubo ◽  
...  

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 355-355 ◽  
Author(s):  
Sofia Palacio ◽  
Caroline Ripat ◽  
Heather Stuart ◽  
Danny Yakoub ◽  
Nipun B. Merchant

355 Background: Pancreatic adenocarcinoma (PDAC) is now the third leading cause of cancer death. Surgical resection followed by adjuvant chemotherapy has been the standard of care. Due to the significant risk of morbidity following pancreatic surgery, initiation of adjuvant chemotherapy is often delayed. Prior prospective adjuvant trials have suggested that adjuvant therapy can be initiated as late as 12 weeks without detriment, but data regarding the effectiveness of beginning adjuvant therapy beyond that time remains unknown. Methods: We retrospectivelyreviewed data from the National Cancer Data Base (2004-2014) and included adult patients (pts) with PDAC with pathologic stage I-IIB who underwent surgical resection with curative intent. The primary outcome was overall survival (OS) based on time to adjuvant chemotherapy post-surgery as defined by postoperative weeks. Data were analyzed using Cox proportional hazard model and Kaplan-Meier survival curves. Results: 5279 pts. had surgery alone and 4,537 pts. received adjuvant chemotherapy. The median age was 64 years. 52% were male, 88% were white, 46% were treated at comprehensive community cancer centers. The primary surgical approach was whipple procedure in 61% of pts. 63% pts. received single agent chemotherapy and the mean time from surgery to chemotherapy was 61 days. Adjuvant chemotherapy was associated with improved OS irrespective of disease stage compared to those undergoing surgery alone (median OS for surgery alone 14 months vs adjuvant chemotherapy 21 months, p < 0.001). Cox proportional hazard model controlling for stage, surgical technique, lymph node dissection and margin status revealed improved OS in pts. receiving adjuvant chemotherapy. No significant differences in OS were seen for pts. starting adjuvant chemotherapy at 3, 6, 9, 12, 16, 20 or 24 weeks after surgical resection. Conclusions: Current guidelines recommend initiation of adjuvant chemotherapy prior to 12 weeks after pancreatic resection. Initiating adjuvant chemotherapy even up to six months post-operatively improves OS compared to those undergoing surgery alone. Our data supports the use of adjuvant chemotherapy if indicated regardless of time of surgery.


Sign in / Sign up

Export Citation Format

Share Document